OBJECTIVES: A dendritic cell-based cancer vaccine has recently received Food and Drug Administration approval in the USA based on its ability to prolong the survival of prostate cancer patients with advanced disease. However, tumor-mediated immunosuppressive mechanisms might represent an obstacle to optimal performance of this therapy. We have recently shown that monocytes from the blood of prostate cancer patients can fully mature to dendritic cells only after the tumor is removed. Here, we have tested the hypothesis that these tumor-driven monocytes correspond to the recently described subset of CD14(+) HLA-DR(low) immunosuppressor cells. METHODS: Prostate cancer patients were studied before and 1 month after prostatectomy. Pre- and postsurgical patients with colorectal cancer were also included for comparison. Flow cytometric analysis was applied to define CD14(-) HLA-DR(low) CD33(+) CD11b(+) (myeloid) and CD14(+) HLA-DR(low) (monocytic) suppressor cells. Interferon-γ release was used to assess the immunocompetence of lymphocytes. RESULTS: In both prostate cancer and colorectal cancer patients, the percentage of CD14(+) HLA-DR(low) cells was several-fold higher compared with normal subjects. This was not the case for CD14(-) HLA-DR(low) CD33(+) CD11b(+) cells. Furthermore, postsurgical normalization of CD14(+) HLA-DR(low) cells only occurred in prostate cancer patients. In all patients, the interferon-γ response of T lymphocytes to phorbolmyristate acetate-ionomycin was higher compared with normal donors, but it was further increased after tumor ablation only in prostate cancer patients. CONCLUSIONS: The direct link between CD14(+) HLA-DR(low) increase and presence of primary tumor suggests a distinguishing immunosuppressive profile of prostate cancer. This observation supports the principle that the appropriate setting for prostate cancer vaccine therapy is a minimal disease status.
OBJECTIVES: A dendritic cell-based cancer vaccine has recently received Food and Drug Administration approval in the USA based on its ability to prolong the survival of prostate cancerpatients with advanced disease. However, tumor-mediated immunosuppressive mechanisms might represent an obstacle to optimal performance of this therapy. We have recently shown that monocytes from the blood of prostate cancerpatients can fully mature to dendritic cells only after the tumor is removed. Here, we have tested the hypothesis that these tumor-driven monocytes correspond to the recently described subset of CD14(+) HLA-DR(low) immunosuppressor cells. METHODS:Prostate cancerpatients were studied before and 1 month after prostatectomy. Pre- and postsurgical patients with colorectal cancer were also included for comparison. Flow cytometric analysis was applied to define CD14(-) HLA-DR(low) CD33(+) CD11b(+) (myeloid) and CD14(+) HLA-DR(low) (monocytic) suppressor cells. Interferon-γ release was used to assess the immunocompetence of lymphocytes. RESULTS: In both prostate cancer and colorectal cancerpatients, the percentage of CD14(+) HLA-DR(low) cells was several-fold higher compared with normal subjects. This was not the case for CD14(-) HLA-DR(low) CD33(+) CD11b(+) cells. Furthermore, postsurgical normalization of CD14(+) HLA-DR(low) cells only occurred in prostate cancerpatients. In all patients, the interferon-γ response of T lymphocytes to phorbolmyristate acetate-ionomycin was higher compared with normal donors, but it was further increased after tumor ablation only in prostate cancerpatients. CONCLUSIONS: The direct link between CD14(+) HLA-DR(low) increase and presence of primary tumor suggests a distinguishing immunosuppressive profile of prostate cancer. This observation supports the principle that the appropriate setting for prostate cancer vaccine therapy is a minimal disease status.
Authors: Gal Wald; Kerri T Barnes; Megan T Bing; Timothy P Kresowik; Ann Tomanek-Chalkley; Tamara A Kucaba; Thomas S Griffith; James A Brown; Lyse A Norian Journal: Urol Oncol Date: 2014-04-24 Impact factor: 3.498
Authors: Michelle N Messmer; Colleen S Netherby; Debarati Banik; Scott I Abrams Journal: Cancer Immunol Immunother Date: 2014-11-29 Impact factor: 6.968
Authors: In-Young Jung; Simon F Lacey; Andrew J Rech; Megan M Davis; Carl H June; Joseph A Fraietta; Naomi B Haas; Vivek Narayan; Julie S Barber-Rotenberg; Wei-Ting Hwang; Priti Lal; Erica L Carpenter; Shannon L Maude; Gabriela Plesa; Neha Vapiwala; Anne Chew; Michael Moniak; Ronnie A Sebro; Michael D Farwell; Amy Marshall; Joan Gilmore; Lester Lledo; Karen Dengel; Sarah E Church; Tyler D Hether; Jun Xu; Mercy Gohil; Thomas H Buckingham; Stephanie S Yee; Vanessa E Gonzalez; Irina Kulikovskaya; Fang Chen; Lifeng Tian; Kyle Tien; Whitney Gladney; Christopher L Nobles; Hayley E Raymond; Elizabeth O Hexner; Donald L Siegel; Frederic D Bushman Journal: Nat Med Date: 2022-03-21 Impact factor: 87.241
Authors: Vincenzo Bronte; Sven Brandau; Shu-Hsia Chen; Mario P Colombo; Alan B Frey; Tim F Greten; Susanna Mandruzzato; Peter J Murray; Augusto Ochoa; Suzanne Ostrand-Rosenberg; Paulo C Rodriguez; Antonio Sica; Viktor Umansky; Robert H Vonderheide; Dmitry I Gabrilovich Journal: Nat Commun Date: 2016-07-06 Impact factor: 14.919
Authors: Xin Lu; James W Horner; Erin Paul; Xiaoying Shang; Patricia Troncoso; Pingna Deng; Shan Jiang; Qing Chang; Denise J Spring; Padmanee Sharma; John A Zebala; Dean Y Maeda; Y Alan Wang; Ronald A DePinho Journal: Nature Date: 2017-03-20 Impact factor: 49.962